While the reduction in price target from $89 to $85 by UBS could be seen as a negative adjustment, the maintenance of a Buy rating by analyst Eliana Merle suggests a continued positive outlook on the company's fundamentals. This mixed signal might lead to a neutral short-term impact on the stock price, as the market digests both the endorsement of the company's potential and the slight tempering of expectations.